LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progressing after docetaxel

Bookmark and Share
Published: 30 May 2020
Views: 293
Rating:
Save
Prof Michael Hofman - Peter MacCallum Cancer Centre, Melbourne, Australia

Prof Michael Hofman speaks to ecancer about the preliminary results from the ANZUP TheraP trial, presented as part of the ASCO 2020 Virtual Meeting.

The randomised phase II is of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel.

Prof Hofman reports that the results suggest LuPSMA has higher efficacy and lower toxicity than cabazitaxel.

He discusses the next steps of the study and the potential impacts of this study along with other parallel trials.